AZD3355 (LESOGABERAN) FOR TREATMENT AND PREVENTION OF NONALCOHOLIC STEATOHEPATITIS (NASH), LIVER FIBROSIS, AND OTHER LIVER CONDITIONS

Number of patents in Portfolio can not be more than 2000

United States of America

APP PUB NO 20250082654A1
SERIAL NO

18886713

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods of treatment or prevention of fatty liver disease, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma and related liver disease and conditions by administering an effective amount of a GABAB agonist, lesogaberan (AZD3355), or related compounds.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIONE GUSTAVE L LEVY PLACE BOX 1675 NEW YORK NY 10029

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
BECKER, Christine New York, US 3 0
BHATTACHARYA, Dipankar New York, US 52 924
DUDLEY, Joel New York, US 5 16
FRIEDMAN, Scott New York, US 10 14
READHEAD, Benjamin New York, US 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation